Screener
D&A at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Emergent Biosolutions in its filing.
Tagged under the XBRL concept us-gaap:DepreciationDepletionAndAmortization.
The source filing: Emergent Biosolutions’s 10-Q, filed August 6, 2026.
- Filed
- Aug 5, 2026, 8:00 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001367644-26-000082
| Line item | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Net income (loss) | $(173.4) | $56.0 |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||
| Stock-based compensation expense | 8.8 | 6.1 |
| Depreciation and amortization | 47.5 | 48.9 |
| Amortization of deferred financing costs | 3.4 | 4.7 |
| Deferred income taxes | (2.4) | 4.7 |
| Noncash loss on assets held-for-sale | 10.7 | 12.2 |
| Change in fair value of warrant liability | (8.9) | (6.6) |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Emergent Biosolutions's D&A?
- Emergent Biosolutions (EBS) reported D&A of $24M in Q2 2026.
- How has Emergent Biosolutions's D&A changed year-over-year?
- Emergent Biosolutions's D&A increased by 2.1% year-over-year, from $23.5M to $24M.
- What is the long-term trend for Emergent Biosolutions's D&A?
- Over 4 years (2021 to 2025), Emergent Biosolutions's D&A has grown at a -6.2% compound annual growth rate (CAGR), from $123.8M to $95.8M.
- What does D&A mean?
- Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.
Ask your AI about Emergent Biosolutions's d&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude